Long-term blockade of IL-1 has been found to restore the clinical equilibrium in systemic inflammasomopathies of childhood, also if involving the central nervous system [94,95], and IL-1 inhibitors have become cardinal weapons in managing both monogenic innate immunity defects and a plethora of polygenic diseases occurring in children, including Kawasaki disease [96]. The gene discussed is IL1A; the disease is Kawasaki disease.